Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Adams Respiratory Leaves Texas for NJ; Two Appointments Announced

By Pharmaceutical Processing | May 17, 2004

CHESTER, NJ (May 17, 2004) – Adams Respiratory Therapeutics, a maker of specialty pharmaceuticals for respiratory care, announced last week the relocation of its corporate headquarters from Fort Worth, Texas, to Chester, New Jersey.

A new 14,000 square-foot facility will house the company’s executive offices, including sales, marketing, finance, business development and legal.

Referring to the Chester-area as “the hub of pharmaceutical development and marketing,” Michael J. Valentino, president and chief executive officer, termed the move a “strategic step” in the company’s effort to grow its respiratory product portfolio. Meanwhile, H. F. (Harry) Oberkfell, age 57, was appointed to the Adams board of directors, increasing the board size to eight and Robert Casale, age 45, was appointed to the new position of vice president, OTC marketing and business development.

Oberkfell was an officer with Warner-Lambert for more than 30 years, serving as chief knowledge officer, president of the company’s Latin America/Asia sector and president of the company’s North American Parke-Davis subsidiary. In the former two positions, Oberkfell led the launches of Lipitor and Rezulin in Latin America and Asia, and initiated a company-wide knowledge resource initiative.

Casale, prior to joining Adams, served as a vice president of marketing for both Warner-Lambert and Pfizer Consumer Healthcare. In his new position, Casale will be responsible for OTC marketing and the external sourcing of new business opportunities, the company said.

Adams Respiratory Therapeutics develops, markets and sells prescription and non-prescription pharmaceuticals for the treatment of respiratory disorders and diseases.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE